Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-PD1/PDL1 Antibody”

82 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 82 results

Not applicableUnknownNCT05349045
What this trial is testing

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer

Who this might be right for
Esophageal Neoplasms
The First Affiliated Hospital of Zhengzhou University 300
Large-scale testing (Phase 3)Looking for participantsNCT07044336
What this trial is testing

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Who this might be right for
Endometrial CancerMalignant Solid Tumour
AstraZeneca 700
Testing effectiveness (Phase 2)Active Not RecruitingNCT06449209
What this trial is testing

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Who this might be right for
Extensive-stage Small-cell Lung CancerSmall-cell Lung Cancer
BioNTech SE 110
Not applicableNot Yet RecruitingNCT05660213
What this trial is testing

Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer

Who this might be right for
Unresectable Hepatocellular Carcinoma
Fudan University 750
Testing effectiveness (Phase 2)Study completedNCT02694822
What this trial is testing

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Who this might be right for
Advanced Solid CancersAdvanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Agenus Inc. 89
Testing effectiveness (Phase 2)Study completedNCT03642067
What this trial is testing

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Who this might be right for
Microsatellite Stable (MSS) Colorectal AdenocarcinomasColorectal Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 59
Large-scale testing (Phase 3)Looking for participantsNCT06382129
What this trial is testing

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 680
Testing effectiveness (Phase 2)Study completedNCT03727880
What this trial is testing

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Who this might be right for
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal Adenocarcinoma
Lei Zheng 28
Testing effectiveness (Phase 2)UnknownNCT03085069
What this trial is testing

Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms Nec+4 more
Jiangsu HengRui Medicine Co., Ltd. 146
Testing effectiveness (Phase 2)UnknownNCT05129189
What this trial is testing

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression

Who this might be right for
HIV Infections
Shanghai Public Health Clinical Center 15
Not applicableUnknownNCT04639284
What this trial is testing

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 200
Testing effectiveness (Phase 2)Looking for participantsNCT06941857
What this trial is testing

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Testing effectiveness (Phase 2)Looking for participantsNCT05426005
What this trial is testing

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Sun Yat-sen University 28
Testing effectiveness (Phase 2)Study completedNCT04732494
What this trial is testing

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
BeiGene 125
Testing effectiveness (Phase 2)Ended earlyNCT04438382
What this trial is testing

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmSteroid-Refractory Pneumonitis
ECOG-ACRIN Cancer Research Group 1
Early research (Phase 1)Ended earlyNCT05069935
What this trial is testing

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Who this might be right for
Solid Tumor, Adult
Fate Therapeutics 16
Early research (Phase 1)UnknownNCT04756934
What this trial is testing

HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Who this might be right for
Melanoma
Taizhou HoudeAoke Biomedical Co., Ltd. 63
Large-scale testing (Phase 3)Active Not RecruitingNCT05785767
What this trial is testing

Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals 850
Testing effectiveness (Phase 2)Active Not RecruitingNCT05215067
What this trial is testing

A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Akeso 44
Testing effectiveness (Phase 2)WithdrawnNCT07038915
What this trial is testing

STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

Who this might be right for
Lung Squamous Cell CarcinomaAnti-PD1/PDL1 Antibody
M.D. Anderson Cancer Center
Load More Results